Skip to main content

. 1969 Oct;32(5):460–461. doi: 10.1136/jnnp.32.5.460

L-dopa and the negative symptoms of Parkinsonism.

H L Klawans Jr, M Erlich

PMCID: PMC496559 PMID: 5360053

460

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

BARBEAU A. The pathogenesis of Parkinson's disease: a new hypothesis. Can Med Assoc J. 1962 Oct 13;87:802–807. [PMC free article] [PubMed] [Google Scholar]
Cotzias G. C., Papavasiliou P. S., Gellene R. Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969 Feb 13;280(7):337–345. doi: 10.1056/NEJM196902132800701. [DOI] [PubMed] [Google Scholar]
Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev. 1966 Jun;18(2):925–964. [PubMed] [Google Scholar]
Klawans H. L., Jr The pharmacology of parkinsonism (a review). Dis Nerv Syst. 1968 Dec;29(12):805–816. [PubMed] [Google Scholar]
McLennan H., York D. H. The action of dopamine on neurones of the caudate nucleus. J Physiol. 1967 Apr;189(3):393–402. doi: 10.1113/jphysiol.1967.sp008175. [DOI] [PMC free article] [PubMed] [Google Scholar]
SANO I., GAMO T., KAKIMOTO Y., TANIGUCHI K., TAKESADA M., NISHINUMA K. Distribution of catechol compounds in human brain. Biochim Biophys Acta. 1959 Apr;32:586–587. doi: 10.1016/0006-3002(59)90652-3. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES